Xia Y, Tunis M C, Frenette C, Katz K, Amaratunga K, Rose S Rhodenizer, House A, Quach C
Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC.
Infection Prevention and Control, Department of Pediatrics, CHU Sainte-Justine, Montreal, QC.
Can Commun Dis Rep. 2019 Jul 4;45(7-8):191-211. doi: 10.14745/ccdr.v45i78a04.
Two vaccines against infections (CDI) are currently in phase III trials. To enable decision-making on their use in public health programs, national disease epidemiology is necessary.
To determine the epidemiology of hospital-acquired CDI (HA-CDI) and community-associated CDI (CA-CDI) in Canada using provincial surveillance data and document discrepancies in CDI-related definitions among provincial surveillance programs.
Publicly-available CDI provincial surveillance data from 2011 to 2016 that distinguished between HA-CDI and CA-CDI were included and the most common surveillance definitions for each province were used. The HA-, CA-CDI incidence rates and CA-CDI proportions (%) were calculated for each province. Both HA- and CA-CDI incidence rates were examined for trends. Types of disparities were summarized and detailed discrepancies were documented.
Canadian data were analyzed from nine provinces. The HA-CDI rates ranged from 2.1/10,000 to 6.5/10,000 inpatient-days, with a decreasing trend over time. Available data on CA-CDI showed that both rates and proportions have been increasing over time. Discrepancies among provincial surveillance definitions were documented in CDI case classifications, surveillance populations and rate calculations.
In Canada overall, the rate of HA-CDI has been decreasing and the rate of CA-CDI has been increasing, although this calculation was impeded by discrepancies in CDI-related definitions among provincial surveillance programs. Nationally-adopted common definitions for CDI would enable better comparisons of CDI rates between provinces and a calculation of the pan-Canadian burden of illness to support vaccine decision-making.
目前有两种针对艰难梭菌感染(CDI)的疫苗正处于III期试验阶段。为了能够就其在公共卫生项目中的使用做出决策,了解国家疾病流行病学情况很有必要。
利用省级监测数据确定加拿大医院获得性CDI(HA-CDI)和社区相关性CDI(CA-CDI)的流行病学情况,并记录省级监测项目中与CDI相关定义的差异。
纳入2011年至2016年可公开获取的区分HA-CDI和CA-CDI的省级CDI监测数据,并使用每个省份最常见的监测定义。计算每个省份的HA-CDI、CA-CDI发病率以及CA-CDI所占比例(%)。同时研究HA-CDI和CA-CDI发病率的趋势。总结差异类型并记录详细的差异情况。
分析了加拿大九个省份的数据。HA-CDI发病率在每10000住院日2.1至6.5例之间,且随时间呈下降趋势。现有CA-CDI数据显示,发病率和所占比例均随时间增加。在CDI病例分类、监测人群和发病率计算方面记录了省级监测定义之间的差异。
总体而言,在加拿大,HA-CDI发病率一直在下降,而CA-CDI发病率一直在上升,尽管由于省级监测项目中与CDI相关定义的差异,这一计算受到了阻碍。全国采用统一的CDI定义将有助于更好地比较各省之间的CDI发病率,并计算加拿大全国的疾病负担,以支持疫苗决策。